Articles |
From the Departments of Medicine (F.P., A.M.F., J.A.B.) and Pathology (Z.T.F., B.Y., J.A.B.), UCLA School of Medicine, Los Angeles, Calif.
Correspondence to Farhad Parhami, Division of Cardiology, UCLA Center for Health Sciences, Rm 47-123, 10833 Le Conte Ave, Los Angeles, CA 90095.
| Abstract |
|---|
|
|
|---|
Key Words: minimally oxidized LDL G proteins cAMP ADP ribosylation
| Introduction |
|---|
|
|
|---|
Many review articles have described the regulatory mechanisms for the
activity of AC, the family of enzymes responsible for cAMP formation in
cells.7 8 Briefly, AC activity is regulated by the
Gs-mediated stimulatory and Gi-mediated
inhibitory arms of the AC system.7 The
activation of Gs complexes occurs as the result of
interaction with a ligand-bound stimulatory receptor, followed by
the dissociation of the
subunit from the ß and
subunits
and the activation of AC by these subunits. The dissociation of the
subunits involves the exchange of a GDP for a GTP molecule, hence
the GTP dependence of the activation process. Inhibition of AC occurs
via a similar pathway mediated by the dissociation of the
subunit
of Gi complexes from their ß and
subunits. In several
systems AC activity is under tonic inhibition by Gi
complexes.9 10 Inhibition of these Gi
complexes by PT-catalyzed ADP ribosylation of their
subunit leads
to the potentiation of the effects of the stimulatory arm of the AC
system as well as the elevation of basal cAMP levels.9 10
The G proteinindependent alteration of AC activity due to changes
in the physical characteristics of cellular plasma membrane after lipid
incorporation has also been reported.11 12 The present
study addresses the following questions. Does MM-LDL cause the
receptor-mediated activation of Gs complexes, thereby
causing the stimulation of AC activity? Does MM-LDL impair the function
of Gi complexes, thus potentiating the stimulation of AC?
Does MM-LDL affect the activity of AC independent of the effects on G
proteins?
| Methods |
|---|
|
|
|---|
MM-LDL was made by enzymatic modification by using soybean lipoxygenase and phospholipase A26 or by mild oxidation with iron.6 The preparations of MM-LDL used for these studies contained between 20 and 50 pg lipopolysaccharide/mL medium. Both methods of MM-LDL preparation caused minimal oxidation, giving 2 to 3 nmol of thiobarbituric acidreactive substances per milligram of cholesterol after dialysis. The concentrations of lipoproteins used in this study are reported in micrograms of protein. The two methods of lipoprotein modification gave preparations of MM-LDL with similar activity. Each preparation of modified lipoprotein was used at a concentration determined to elicit maximal cellular response.
cAMP Measurement
HAECs were cultured in six-well dishes, and cells were
treated with or without agonists in medium 199 containing 5% fetal
calf serum and 82 µmol/L IBMX (Calbiochem Corp), a phosphodiesterase
inhibitor. After incubation, the cells were rinsed twice
with phosphate-buffered saline containing 4 mmol/L EDTA (also an
inhibitor of cAMP phosphodiesterase) and scraped into the
same buffer. The cell pellet after centrifugation was
resuspended in 200 µL boiling assay buffer (cAMP RIA kit, Amersham
Corp). The suspension was sonicated, heated 5 minutes in a
boiling-water bath, and microcentrifuged for 3 minutes
at high speed to spin out the coagulated proteins. The supernatant was
used to determine cAMP levels normalized to cell number.
Membrane Preparation
HAECs were cultured in 100-mm dishes, and cells were left
untreated or treated with agonist in medium 199 containing 5% fetal
calf serum. Membrane was prepared by one of the following methods, both
of which gave similar results when used in assays. Crude membrane
preparation was made by rinsing the cells twice with cold
phosphate-buffered saline containing 0.1 mmol/L PMSF (a protease
inhibitor; Sigma), after which the cells were scraped into
the same buffer. After centrifugation the cell pellet
was resuspended in 250 µL of 10 mmol/L Tris-HCl buffer, pH 7.5,
containing 1 mmol/L dithiothreitol, 0.1 mmol/L PMSF, 1 µmol/L each
pepstatin and leupeptin (protease inhibitors; Sigma), 5
mmol/L MgCl2, and 1 mmol/L EDTA. The resuspended
cell pellet was then subjected to three rounds of freeze-thawing in
dry iceethanol to disrupt the cells. The suspension was
microcentrifuged at 4°C for 10 minutes at
14 000g to obtain the pellet designated as the membrane
fraction. The pellet was resuspended in 100 mmol/L potassium phosphate
buffer, pH 7.5, containing 5 mmol/L MgCl2 and PMSF,
pepstatin, and leupeptin at the same concentrations as before. The
suspension was then sonicated for 10 seconds, and aliquots were used
for protein determination. As an alternate method, partially purified
membrane fractions were prepared by collecting the cell pellet as
described above and freeze/thawing to disrupt the cells. The cells were
centrifuged for 5 minutes at 500g to separate
cellular organelles, and the supernatant from the first spin was
further centrifuged for 10 minutes at 4°C at
14 000g to obtain the partially purified membrane
pellet.
AC Assay
HAEC membranes were prepared as described above. Assay buffer
consisting of 50 mmol/L Tris-HCl, pH 7.5, 1 mmol/L IBMX, 1.5 mmol/L
EDTA, 1 mmol/L dithiothreitol, 5 mmol/L MgCl2,
0.25% bovine serum albumin, and 0.1 mmol/L PMSF was put in all
assay tubes for a total reaction volume of 100 µL. ATP (Sigma) was
added to all tubes (final concentration, 1 mmol/L). GTP was also added
to each tube (final concentration, 0.5 mmol/L). GTP was also added to
each tube (final concentration, 0.5 unless stated otherwise). If
testing the ability of MM-LDL, IP, or PAPC to activate AC,
these agonists were also added to the appropriate tubes. Finally, 5
µg membrane preparation was placed in each assay tube (except in the
control tube that lacked membrane). Tubes were incubated for 15 minutes
at 30°C, after which the reaction was stopped by adding 800 µL
boiling cAMP assay buffer and heating for 5 minutes in a
boiling-water bath. The tubes were then
microcentrifuged for 3 minutes at high speed to spin out
the coagulated proteins, and the supernatant was used to determine cAMP
content as described above. This method measures the amount of cAMP
formed as determined by RIA, in contrast to the formation of labeled
cAMP derived from labeled ATP as used by other investigators. In
addition, the present method does not require the separation of
labeled cAMP from ATP due to the specificity of the RIA system.
ADP Ribosylation
HAEC membranes were prepared as described above. Membrane
preparation (15 µg) was placed in each assay tube, except in the
control tube without membrane. Assay buffer was added that consisted of
100 mmol/L potassium phosphate, 5 mmol/L MgCl2, 0.1
mmol/L PMSF, 1 µmol/L each leupeptin and pepstatin, 10 mmol/L
dithiothreitol, 4 mmol/L thymidine, 1 mmol/L ATP, 1 mmol/L GTP, and 20
µg ovalbumin for a total volume of 200 µL. To each tube
8 µCi (0.2 µmol/L) nicotinamide
adenine[
-32P]dinucleotide (ICN
Radiochemicals) and 2.5 µg/mL activated PT (Calbiochem) were
added. PT was activated by incubation at 25 µg/mL in 20
mmol/L dithiothreitol at 30°C for 15 minutes. Tubes were incubated
for 30 minutes at 30°C, and the reaction was stopped by the addition
of 800 µL ice-cold 13% TCA. TCA-precipitated pellets were
obtained by microcentrifugation at
14 000g for 10 minutes at 4°C; the pellets were rinsed
once with 13% TCA and twice with cold acetone. The acetone was
discarded, and the pellets were dissolved in SDS loading buffer, heated
for 10 minutes in a boiling-water bath, and analyzed in an
11% gel by using SDS-PAGE followed by
autoradiography. The signals were analyzed
by densitometric scanning and are reported in relative densitometric
units that describe the extent of ADP ribosylation in each sample.
Western Blotting
Membrane fractions were prepared as described above, and 15 µg
was resuspended in SDS buffer containing ß-mercaptoethanol.
Proteins were separated by using PAGE and transferred to nitrocellulose
membrane. The membrane was then incubated with antibody to
Gi
1,2 (Biodesign International),
and antibody was detected by chemiluminescence by using the Amersham
ECL reaction system. A band at 41 Kd was
detected that corresponds to the position of
Gi
2.
| Results |
|---|
|
|
|---|
|
MM-LDL Does Not Directly Activate AC
Because one mechanism by which MM-LDL may elevate cAMP levels is
by a G proteinindependent activation of AC, we examined the
activity of the enzyme in membrane preparations from untreated cells
and cells treated with MM-LDL in the absence of exogenously added GTP
or stimulatory agonists. No increase in AC activity was detected in
membrane preparations from MM-LDLtreated versus untreated control
cells (4.1 versus 4.2 fmol
cAMP·mg-1·min-1,
respectively; n=6, P=.447). These data suggest that MM-LDL
does not directly activate AC in these cells.
Activation of Gs by MM-LDL
To examine the role of Gs in activation of AC by
MM-LDL, several approaches were taken. To detect
Gs-specific increases in AC activity, the possible
contribution from MM-LDLinduced Gi inhibition must be
eliminated. This was achieved by using PT, an enzyme that has been
shown to inhibit receptorGi protein interaction by
ADP-ribosylating the Gi
subunits.14
Incubation of HAECs for 4 hours with 1 µg/mL PT or 125 µg/mL MM-LDL
but not native LDL caused significant elevation of cAMP levels (Fig 2
). Preincubation with 1 µg/mL PT for 4
hours caused the complete inhibition of ADP ribosylation by PT (Fig 2
), an indication of maximal inhibition of all possible
receptor-Gi interactions.15 When cells were
treated for 4 hours with both 1 µg/mL PT and 125 µg/mL MM-LDL, an
additional increase of 32% in cAMP levels was observed compared with
that induced by PT alone (P<.005 for PT plus MM-LDL versus
PT); native LDL did not have an effect similar to MM-LDL (Fig 2
). IP, a ß-adrenergic receptor agonist that
activates AC via activation of Gs, also
caused an increase in cAMP levels when added in combination with PT,
although the increase was much greater than that seen for MM-LDL (Fig 2
).
|
Activation of AC by MM-LDL Is GTP Dependent
To further determine whether MM-LDL increased cAMP by a
Gs-dependent activation of AC activity, membranes were
isolated from HAECs pretreated with 20 ng/mL PT for 4 hours to inhibit
Gi complexes. This two-step isolation (described in
"Methods") resulted in partially purified membranes that showed
no further ADP ribosylation by PT, indicating the complete inhibition
of Gi. GTP (0.5 mmol/L), MM-LDL (500 µg/mL), oxidized
PAPC, or IP were added separately or in combination with the membrane
preparations for 15 minutes, and cAMP synthesis was measured by RIA
(Fig 3
). Oxidized PAPC was used because
in a separate study we have shown that the major activity of MM-LDL is
derived from oxidized PAPC.24 GTP caused an
40%
increase in cAMP synthesis in isolated membranes. Both MM-LDL and
oxidized PAPC in the absence of GTP caused increases in cAMP levels
formed. The addition of GTP to PAPC or MM-LDL caused additional 85%
and 40% increases in AC activity, respectively, compared with those
induced in the absence of exogenous GTP. IP increased AC activity
twofold in the absence and sevenfold in the presence of GTP compared
with control membranes (data not shown). Overall, these data show that
MM-LDL and oxidized PAPC stimulate cAMP synthesis by a
Gs-mediated pathway.
|
Effects of MM-LDL on Gi Molecules
The effect of MM-LDL treatment of ECs was also examined. Western
blot analysis of HAEC membranes using an antibody to
Gi
2 detected a band at 41
Kd (Fig 4
). In two
separate experiments, incubation of cells for 4 hours with 125 µg/mL
MM-LDL had no effect on the levels of membrane-associated
Gi
2; however, in those same
experiments ADP ribosylation of
Gi
2 by PT was inhibited by 54%
(Fig 5
). MM-LDLinduced inhibition
ranged between 40% and 60% in five different experiments. Similarly,
incubation of cells with 1 µg/mL PT caused a 95% inhibition of ADP
ribosylation by PT (Fig 5
). In addition, inhibition of
PT-catalyzed ADP ribosylation of an 80-Kd
protein was observed following MM-LDL treatment. The identity of this
molecule, which was not immunoreactive with the antibody to
Gi
2, is presently
unknown to us.
|
|
MM-LDL Pretreatment Inhibits Receptor-Mediated Activation of
Gi by Serotonin
To further characterize the effect of MM-LDL on Gi
activity, the ability of serotonin and mastoparan to
activate Gi molecules in membrane preparations from
untreated versus MM-LDLtreated cells was tested. PT only ADP
ribosylates Gi molecules in their trimeric form, and
receptor-mediated activation of Gi by agonists such as
serotonin or activation by direct Gi
activators such as mastoparan results in dissociation of
the
subunit from the ß and
subunits, thereby inhibiting ADP
ribosylation.14 Previous reports have examined the
interaction of membrane receptors with Gi molecules by
assessing the inhibition of PT-catalyzed ADP ribosylation of
Gi.16 Incubation of membranes from untreated
HAECs with serotonin resulted in a 60% inhibition of ADP
ribosylation by PT (Fig 6
). However,
serotonin did not inhibit ADP ribosylation in membrane
preparations from MM-LDLtreated cells (Fig 6
).
Although in several experiments the degree of MM-LDL effect varied
depending on the activity of the MM-LDL preparation used, there was
always an inhibitory effect on the ability of
serotonin to activate Gi molecules.
Mastoparan caused a 95% inhibition of PT-catalyzed ADP ribosylation in
membrane preparations of untreated cells. In contrast to
serotonin, the ability of mastoparan to activate
Gi molecules and inhibit ADP ribosylation was not inhibited
in membrane preparations from MM-LDLtreated cells (Fig 7
).
|
|
| Discussion |
|---|
|
|
|---|
The activation of Gs molecules appears to be a partial
explanation of the mechanism by which MM-LDL elevates cAMP levels in
aortic ECs. Our present study indicates that MM-LDL causes several
effects on endothelial Gi molecules.
Incubation of ECs with MM-LDL but not native LDL significantly
inhibited PT-catalyzed ADP ribosylation of Gi (Fig 5
). The mechanism by which MM-LDL may cause such an
effect is not known; however, posttranslational modification of the
Gi molecules may be involved. One possibility may be the
activation of a cellular ADP ribosyltransferase17 that
would ADP ribosylate the sites normally targeted by PT. Activation of
cellular ADP ribosyltransferases has been reported for other EC
activators, such as L-arginine,18
the precursor of endothelium-derived nitric oxide,
a potent vasodilator. Alternatively, MM-LDL may alter the PT binding
sites, thereby blocking their interaction with PT. The effect of MM-LDL
is not due to a decrease in the total amount of membrane-associated
Gi
2 (Fig 4
).
Our observations also indicate that MM-LDL interferes with receptor
activation of Gi molecules, as suggested by the complete
inhibition of serotonin-induced Gi
activation and PT-catalyzed ADP ribosylation in membranes from
MM-LDLtreated cells (Fig 6
). This effect appears to be
specifically at the level of Gi-receptor interaction, since
the direct activation of Gi by mastoparan was not affected
(Fig 4
). MM-LDL may inhibit the site of interaction with
inhibitory receptors, which may be close if not similar to
the site of ADP ribosylation by PT. Impaired Gi-mediated
function of the endothelium from atherosclerotic
vessels has been reported.19 Similar results have been
reported for the ability of lysophosphatidylcholine, a component of
oxidized LDL, to inhibit receptor-mediated activation of
Gi molecules in ECs.20 Lysophosphatidylcholine
is unlikely to be responsible for inhibition of ADP ribosylation by
MM-LDL, as by itself it does not increase cAMP levels in HAECs, and
very low levels of lysophosphatidylcholine are present in the
iron-oxidized LDL used for several of the ADP ribosylation studies
(less than 1 µmol/L when MM-LDL is added to the cells at 125
µg/mL). In addition, Liao21 has shown the inhibition of
bradykinin-stimulated, Gi-mediated release of nitric
oxide in bovine aortic ECs treated for 72 hours with LDL. This effect
may have been caused as a result of cell-mediated oxidation of LDL.
Liao and Clark22 have further reported that such prolonged
treatment of cells with LDL oxidized to a greater degree than the LDL
used in the present studies causes a decrease in the level of
expression of Gi
2. Thus, the
results of previous studies and the present one show that
Gi inhibition in response to products of lipid
oxidation may only involve alterations in the interaction of receptors
with Gi complexes or may, under more severe conditions,
involve actual loss of the Gi protein. An extensive review
by Flavahan23 describes the potential mechanisms underlying
the impaired Gi-mediated endothelial
signaling associated with atherosclerosis.
We have identified an oxidized phospholipid in MM-LDL that is responsible for its ability to induce monocyte adherence to ECs and that is a target for inactivation by the platelet-activating factor acetylhydrolase.24 Our preliminary observations suggest that the phospholipids isolated from MM-LDL elevate cAMP levels in aortic ECs. We are currently further characterizing the active lipid components in MM-LDL that are responsible for stimulating AC activity. Here we have presented evidence that MM-LDL activates aortic ECs by interacting with their Gs as well as their Gi molecules. If the present in vitro study indicates the events occurring in vivo, our observations suggest that several pathways would need to be targeted to control endothelial activation in atherosclerosis.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received January 11, 1995; accepted September 1, 1995.
| References |
|---|
|
|
|---|
2.
Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima
A, Yoshida H, Kawai C. Probucol prevents the progression of
atherosclerosis in Watanabe heritable
hyperlipidemic rabbit, an animal model for familial
hyperlipidemia. Proc Natl Acad Sci
U S A. 1987;84:5928-5931.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500. [Medline] [Order article via Infotrieve]
4. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
5.
Cushing SD, Berliner JA, Valentine AJ, Territo MC,
Navab M, Parhami F, Gerrity R, Schwarz CJ, Fogelman AM.
Minimally modified low density lipoprotein induces monocyte chemotactic
protein 1 in human endothelial cells and smooth muscle
cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
6. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.
7. Reithmann C, Gierschik P, Jacobs KH. Stimulation and inhibition of adenylate cyclase. Symp Soc Exp Biol. 1990;44:207-224. [Medline] [Order article via Infotrieve]
8. Tang WJ, Gilman AG. Adenylyl cyclases. Cell. 1992;70:869-872. [Medline] [Order article via Infotrieve]
9. Hsia JA, Moss J, Hewlett EL, Vaughan M. Requirement for both choleragen and pertussis toxin to obtain maximal activation of adenylate cyclase in cultured cells. Biochem Biophys Res Commun. 1984;119:1068-1074. [Medline] [Order article via Infotrieve]
10.
Olansky L, Myers GA, Pohl SL, Hewlett EL.
Promotion of lipolysis in rat adipocytes by pertussis toxin, reversal
of endogenous inhibition. Proc Natl Acad Sci
U S A. 1983;80:6547-6551.
11. Laychock SG. Coordinate interaction of cyclic nucleotide phospholipid metabolizing pathways in calcium-dependent cellular responses. Curr Top Cell Regul. 1989;30:203-242. [Medline] [Order article via Infotrieve]
12.
Engelhard VH, Esko JD, Storm DR, Glaser M.
Modification of adenylate cyclase activity in LM cells by
manipulation of membrane phospholipid composition in vivo.
Proc Natl Acad Sci U S A. 1976;73:4482-4486.
13.
Berliner JA, Territo MC, Almada L, Carter A, Shafonsky
E, Fogelman AM. Monocyte chemotactic factor produced by
large-vessel endothelial cells in vitro.
Arteriosclerosis. 1986;6:254-258.
14. Moss J, Vaughan M. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv Enzymol Relat Areas Mol Biol. 1988;61:303-379. [Medline] [Order article via Infotrieve]
15. Gold MR, Jakway JP, DeFranco AL. Involvement of a guanine-nucleotide-binding component in membrane IgM-stimulated phosphoinositide breakdown. J Immunol. 1987;139:3604-3613. [Abstract]
16.
Wilhelm B, Siess W. Activation of cloned
platelet thrombin receptor decreases the
pertussis-toxin-dependent ADP-ribosylation of the membrane and
soluble inhibitory
guanine-nucleotide-binding-
proteins.
Eur J Biochem. 1993;216:81-88. [Medline]
[Order article via Infotrieve]
17. Ueda K. ADP-ribosylation. Annu Rev Biochem. 1985;54:73-100. [Medline] [Order article via Infotrieve]
18. Dimmeler S, Brune B. L-arginine stimulates an endogenous ADP-ribosyltransferase. Biochem Biophys Res Commun. 1991;178:848-855. [Medline] [Order article via Infotrieve]
19.
Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of
endothelial pertussis toxinsensitive G protein
function in atherosclerotic porcine coronary arteries.
Circulation. 1991;83:652-660.
20.
Flavahan NA. Lysophosphatidylcholine modifies G
protein-dependent signaling in porcine endothelial
cells. Am J Physiol. 1993;264:H722-H727.
21.
Liao JK. Inhibition of Gi proteins
by low density lipoprotein attenuates bradykinin-stimulated release
of endothelial-derived nitric oxide.
J Biol Chem. 1994;269:12987-12992.
22. Liao JK, Clark SL. Regulation of G-protein ai2 subunit expression by oxidized low-density lipoprotein. J Clin Invest. 1995;95:1457-1463.
23.
Flavahan NA. Atherosclerosis or
lipoprotein-induced endothelial dysfunction:
potential mechanisms underlying reduction in EDRF/nitric oxide
activity. Circulation. 1992;85:1927-1938.
24. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
This article has been cited by other articles:
![]() |
J. Huber, A. Furnkranz, V. N. Bochkov, M. K. Patricia, H. Lee, C. C. Hedrick, J. A. Berliner, B. R. Binder, and N. Leitinger Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase J. Lipid Res., May 1, 2006; 47(5): 1054 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Leitinger A Rancid Culprit in Vascular Inflammation Acts on the Prostaglandin Receptor EP2 Circ. Res., March 17, 2006; 98(5): 587 - 589. [Full Text] [PDF] |
||||
![]() |
R. Li, K. P. Mouillesseaux, D. Montoya, D. Cruz, N. Gharavi, M. Dun, L. Koroniak, and J. A. Berliner Identification of Prostaglandin E2 Receptor Subtype 2 As a Receptor Activated by OxPAPC Circ. Res., March 17, 2006; 98(5): 642 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu, H. Jiang, and R. W. Grange Genistein Activates the 3',5'-Cyclic Adenosine Monophosphate Signaling Pathway in Vascular Endothelial Cells and Protects Endothelial Barrier Function Endocrinology, March 1, 2005; 146(3): 1312 - 1320. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Cole, G. Subbanagounder, S. Mukhopadhyay, J. A. Berliner, and D. K. Vora Oxidized Phospholipid-Induced Endothelial Cell/Monocyte Interaction Is Mediated by a cAMP-Dependent R-Ras/PI3-Kinase Pathway Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1384 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mackman How Do Oxidized Phospholipids Inhibit LPS Signaling? Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1133 - 1136. [Full Text] [PDF] |
||||
![]() |
I. GOUNI-BERTHOLD and A. SACHINIDIS Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells? FASEB J, October 1, 2002; 16(12): 1477 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Escargueil-Blanc, R. Salvayre, N. Vacaresse, G. Jurgens, B. Darblade, J.-F. Arnal, S. Parthasarathy, and A. Negre-Salvayre Mildly Oxidized LDL Induces Activation of Platelet-Derived Growth Factor {beta}-Receptor Pathway Circulation, October 9, 2001; 104(15): 1814 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tanikawa, H. Kanatsuka, R. Koshida, M. Tanaka, A. Sugimura, T. Kumagai, M. Miura, T. Komaru, and K. Shirato Role of pertussis toxin-sensitive G protein in metabolic vasodilation of coronary microcirculation Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1819 - H1829. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shi, M. E. Haberland, M.-L. Jien, D. M. Shih, and A. J. Lusis Endothelial Responses to Oxidized Lipoproteins Determine Genetic Susceptibility to Atherosclerosis in Mice Circulation, July 4, 2000; 102(1): 75 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Paulson, P. Lampe, R. Meyer, E TenBroek, M. Atkinson, T. Walseth, and R. Johnson Cyclic AMP and LDL trigger a rapid enhancement in gap junction assembly through a stimulation of connexin trafficking J. Cell Sci., January 9, 2000; 113(17): 3037 - 3049. [Abstract] [PDF] |
||||
![]() |
L. J. Pinderski Oslund, C. C. Hedrick, T. Olvera, A. Hagenbaugh, M. Territo, J. A. Berliner, and A. I. Fyfe Interleukin-10 Blocks Atherosclerotic Events In Vitro and In Vivo Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2847 - 2853. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Leitinger, T. R. Tyner, L. Oslund, C. Rizza, G. Subbanagounder, H. Lee, P. T. Shih, N. Mackman, G. Tigyi, M. C. Territo, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils PNAS, October 12, 1999; 96(21): 12010 - 12015. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M Dart and J. P.F Chin-Dusting Lipids and the endothelium Cardiovasc Res, August 1, 1999; 43(2): 308 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Balagopalakrishna, L. Paka, S. Pillarisetti, and I. J. Goldberg Lipolysis-induced iron release from diferric transferrin: possible role of lipoprotein lipase in LDL oxidation J. Lipid Res., July 1, 1999; 40(7): 1347 - 1356. [Abstract] [Full Text] |
||||
![]() |
P. K. WITTING, K. PETTERSSON, A.-M. ÖSTLUND-LINDQVIST, C. WESTERLUND, A. W. ERIKSSON, and R. STOCKER Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice FASEB J, April 1, 1999; 13(6): 667 - 675. [Abstract] [Full Text] |
||||
![]() |
I. Suc, O. Meilhac, I. Lajoie-mazenc, J. Vandaele, G. Jürgens, R. Salvayre, and A. Nègre-salvayre Activation of EGF receptor by oxidized LDL FASEB J, June 1, 1998; 12(9): 665 - 671. [Abstract] [Full Text] |
||||
![]() |
H. E. De Vries, E. Ronken, J.-h. Reinders, B. Buchner, T. J. C. van berkel, and J. Kuiper Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages FASEB J, January 1, 1998; 12(1): 111 - 118. [Abstract] [Full Text] |
||||
![]() |
T. Komaru, T. Tanikawa, A. Sugimura, T. Kumagai, K. Sato, H. Kanatsuka, and K. Shirato Mechanisms of Coronary Microvascular Dilation Induced by the Activation of Pertussis Toxin–Sensitive G Proteins Are Vessel-Size Dependent: Heterogeneous Involvement of Nitric Oxide Pathway and ATP-Sensitive K+ Channels Circ. Res., January 1, 1997; 80(1): 1 - 10. [Abstract] [Full Text] |
||||
![]() |
M. Navab, J. A. Berliner, A. D. Watson, S. Y. Hama, M. C. Territo, A. J. Lusis, D. M. Shih, B. J. Van Lenten, J. S. Frank, L. L. Demer, et al. The Yin and Yang of Oxidation in the Development of the Fatty Streak: A Review Based on the 1994 George Lyman Duff Memorial Lecture Arterioscler Thromb Vasc Biol, July 1, 1996; 16(7): 831 - 842. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |